Assay development and inhibition of the Mt-DprE2 essential reductase from Mycobacterium tuberculosis
Sign Up to like & getrecommendations! Published in 2023 at "Microbiology"
DOI: 10.1099/mic.0.001288
Abstract: DprE2 is an essential enzyme in the synthesis of decaprenylphosphoryl-β-d-arabinofuranose (DPA) and subsequently arabinogalactan, and is a significant new drug target for M. tuberculosis . Two compounds from the GSK-177 box set, GSK301A and GSK032A,… read more here.
Keywords: inhibition; assay development; tuberculosis; dpre2 ... See more keywords
In Vitro Assay Development and HTS of Small-Molecule Human ABAD/17β-HSD10 Inhibitors as Therapeutics in Alzheimer’s Disease
Sign Up to like & getrecommendations! Published in 2017 at "SLAS Discovery"
DOI: 10.1177/2472555217697964
Abstract: A major hallmark of Alzheimer’s disease (AD) is the formation of neurotoxic aggregates composed of the amyloid-β peptide (Aβ). Aβ has been recognized to interact with numerous proteins, resulting in pathological changes to the metabolism… read more here.
Keywords: abad; alzheimer disease; vitro assay; assay development ... See more keywords
UPLC/MS-MS assay development for estimation of mozavaptan in plasma and its pharmacokinetic study in rats.
Sign Up to like & getrecommendations! Published in 2018 at "Bioanalysis"
DOI: 10.4155/bio-2018-0092
Abstract: AIM Mozavaptan is a nonpeptide vasopressin receptor antagonist approved for the treatment of ectopic antidiuretic hormone secretion syndrome. METHODS & RESULTS A simple, rapid and fully validated UPLC/MS-MS method was developed for the quantitation of… read more here.
Keywords: plasma; development estimation; uplc assay; mozavaptan ... See more keywords
Quantification of oxalate by novel LC-MS/MS: assay development, validation and application in lumasiran clinical trials.
Sign Up to like & getrecommendations! Published in 2023 at "Bioanalysis"
DOI: 10.4155/bio-2022-0227
Abstract: Background: Measurement of plasma oxalate (POx) is challenging, but critical, for management of patients with primary hyperoxaluria type 1. A novel LC-MS/MS assay was developed, validated and used to quantify POx in patients with primary hyperoxaluria… read more here.
Keywords: development validation; quantification oxalate; quantification; novel assay ... See more keywords
The Development of Novel N-Terminal Pro-Peptide of Type I Chemiluminescence Assay.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical laboratory"
DOI: 10.7754/clin.lab.2021.210210
Abstract: BACKGROUND P1NP can be used for monitoring patients treated with both bisphosphonates and teriparatide as bone formation markers. P1NP assays include two types, intact trimeric form of P1NP assay and total P1NP assay. In this… read more here.
Keywords: p1np assay; type; p1np; assay development ... See more keywords